董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony Pagano | 男 | Director | 48 | 未披露 | 未持股 | 2026-01-01 |
| Oguzhan Atay | 男 | Chair of the Board and Chief Executive Officer | 38 | 1968.49万美元 | 319.29 | 2026-01-01 |
| Thomas Bremner | 男 | Director | 44 | 未披露 | 193.89 | 2026-01-01 |
| Krishna Swaroop Kolluri | 男 | Director | 62 | 未披露 | 435.95 | 2026-01-01 |
| Firat Ileri | 男 | Director | 39 | 未披露 | 791.62 | 2026-01-01 |
| David Tsao | 男 | President, Chief Technology Officer and Director | 37 | 1004.40万美元 | 302.88 | 2026-01-01 |
| Akshay Rai | 男 | Director | 42 | 未披露 | 178.96 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ross Taylor | 男 | Chief Financial Officer | 63 | 206.24万美元 | 未持股 | 2026-01-01 |
| Thomas Lynch | 男 | Chief Compliance Officer and General Counsel and Secretary | 59 | 未披露 | 未持股 | 2026-01-01 |
| Shan Riku Sakakibara | 女 | Chief Product Officer | 43 | 未披露 | 未持股 | 2026-01-01 |
| John ten Bosch | 男 | Senior Vice President of Laboratory Operations | 51 | 未披露 | 未持股 | 2026-01-01 |
| Oguzhan Atay | 男 | Chair of the Board and Chief Executive Officer | 38 | 1968.49万美元 | 319.29 | 2026-01-01 |
| John Lister | 男 | Chief Administrative Officer | 51 | 333.67万美元 | 未持股 | 2026-01-01 |
| David Tsao | 男 | President, Chief Technology Officer and Director | 37 | 1004.40万美元 | 302.88 | 2026-01-01 |
| Nancy Johnson | 女 | Senior Vice President of Sales and Commercial Operations | 63 | 64.12万美元 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Anthony Pagano
-
Anthony Pagano于2007年加入Genmab。DavidA.Eatwell于2020年2月29日退休后，他在公司任职期间资历不断提升，目前担任公司Vice President和首席财务官的高管。加入公司之前，Pagano从2005年到2007年担任Novadel Pharma，Inc.（一家上市专业制药公司）企业总监和业务规划高级主管。他之前从1999年到2005年在毕马威会计师事务所（KPMG LLP）担任经理。他是一名注册会计师，在新泽西学院（College of New Jersey）获得会计学学士学位，在纽约大学（New York University）斯特恩商学院（Stern School of Business）获得工商管理硕士学位。
Anthony Pagano joined Genmab in 2007. His positions increased in seniority during his tenure with and he currently serves as Genmab A/S Executive Vice President and Chief Financial Officer. Prior to joining , Mr. Pagano was Corporate Controller and Senior Director of Biness Planning at NovaDel Pharma, Inc. from 2005 to 2007, a publicly traded specialty pharmaceutical company. He previoly worked as a Manager at KPMG LLP from 1999 to 2005. In December 2025, Mr. Pagano was appointed to the Board of Directors of BillionToOne and as Audit Committee Chair, effective January 2026. He is a CPA and received a B.S. in Accounting from The College of New Jersey, as ll as an MBA from the Stern School of Biness at New York University. - Anthony Pagano于2007年加入Genmab。DavidA.Eatwell于2020年2月29日退休后，他在公司任职期间资历不断提升，目前担任公司Vice President和首席财务官的高管。加入公司之前，Pagano从2005年到2007年担任Novadel Pharma，Inc.（一家上市专业制药公司）企业总监和业务规划高级主管。他之前从1999年到2005年在毕马威会计师事务所（KPMG LLP）担任经理。他是一名注册会计师，在新泽西学院（College of New Jersey）获得会计学学士学位，在纽约大学（New York University）斯特恩商学院（Stern School of Business）获得工商管理硕士学位。
- Anthony Pagano joined Genmab in 2007. His positions increased in seniority during his tenure with and he currently serves as Genmab A/S Executive Vice President and Chief Financial Officer. Prior to joining , Mr. Pagano was Corporate Controller and Senior Director of Biness Planning at NovaDel Pharma, Inc. from 2005 to 2007, a publicly traded specialty pharmaceutical company. He previoly worked as a Manager at KPMG LLP from 1999 to 2005. In December 2025, Mr. Pagano was appointed to the Board of Directors of BillionToOne and as Audit Committee Chair, effective January 2026. He is a CPA and received a B.S. in Accounting from The College of New Jersey, as ll as an MBA from the Stern School of Biness at New York University.
- Oguzhan Atay
-
Oguzhan Atay是首席执行官兼联合创始人，自2016年成立以来一直领导该公司，同时还担任董事会主席。Atay博士在斯坦福大学获得生物学博士学位，他的工作发表在Cell Systems的封面上。他以优异成绩和Phi Beta Kappa成绩毕业于普林斯顿大学，获得分子生物学学士学位，并辅修物理学、计算机科学和应用数学。
Oguzhan Atay is Chief Executive Officer and Co Founder, having led the Company since its inception in 2016, and also serves as the Chair of Board of Directors. Dr. Atay received his PhD in Biology from Stanford University, where his work was published on the cover of Cell Systems. He graduated summa cum laude and Phi Beta Kappa from Princeton University with a bachelor's in molecular biology and minors in physics, computer science, and applied mathematics. - Oguzhan Atay是首席执行官兼联合创始人，自2016年成立以来一直领导该公司，同时还担任董事会主席。Atay博士在斯坦福大学获得生物学博士学位，他的工作发表在Cell Systems的封面上。他以优异成绩和Phi Beta Kappa成绩毕业于普林斯顿大学，获得分子生物学学士学位，并辅修物理学、计算机科学和应用数学。
- Oguzhan Atay is Chief Executive Officer and Co Founder, having led the Company since its inception in 2016, and also serves as the Chair of Board of Directors. Dr. Atay received his PhD in Biology from Stanford University, where his work was published on the cover of Cell Systems. He graduated summa cum laude and Phi Beta Kappa from Princeton University with a bachelor's in molecular biology and minors in physics, computer science, and applied mathematics.
- Thomas Bremner
-
Thomas Bremner自2022年3月起担任董事会成员。Bremner先生目前是全球私募股权投资管理公司Adams Street Partners，LLC的Growth Equity团队的合伙人，自2013年以来一直受雇于Adams Street。Bremner先生在医疗保健公司的成长和发展方面的经验为董事会提供了对长期战略的独特视角。Bremner先生拥有代顿大学的金融学士学位和芝加哥大学布斯比尼斯学院的MBA学位。
Thomas Bremner is currently a partner of the Growth Equity team of Adams Street Partners, LLC, a global private equity investment management firm, and has been employed by Adams Street since 2013. Mr. Bremner's experience with the growth and development of healthcare companies provides Board of Directors with a unique perspective on long term strategy. Mr. Bremner holds a B.S. in finance from the University of Dayton and an MBA from University of Chicago Booth School of Biness. - Thomas Bremner自2022年3月起担任董事会成员。Bremner先生目前是全球私募股权投资管理公司Adams Street Partners，LLC的Growth Equity团队的合伙人，自2013年以来一直受雇于Adams Street。Bremner先生在医疗保健公司的成长和发展方面的经验为董事会提供了对长期战略的独特视角。Bremner先生拥有代顿大学的金融学士学位和芝加哥大学布斯比尼斯学院的MBA学位。
- Thomas Bremner is currently a partner of the Growth Equity team of Adams Street Partners, LLC, a global private equity investment management firm, and has been employed by Adams Street since 2013. Mr. Bremner's experience with the growth and development of healthcare companies provides Board of Directors with a unique perspective on long term strategy. Mr. Bremner holds a B.S. in finance from the University of Dayton and an MBA from University of Chicago Booth School of Biness.
- Krishna Swaroop Kolluri
-
Krishna Swaroop Kolluri自2019年起担任董事会成员。Kolluri先生作为一名成功的连续创业者、首席执行官、高级运营主管和风险投资家，拥有超过30年的经验。Kolluri先生是Neotribe Ventures的创始合伙人，Neotribe Ventures是一家成立于2017年的投资公司，投资于突破性技术公司。在创立Neotribe之前，Kolluri先生曾于2006年至2016年担任New Enterprise Associates的普通合伙人，专注于早期公司的风险融资。Kolluri先生在印度马德拉斯印度理工学院获得机械工程学士学位，在布法罗大学获得工业工程硕士学位。
Krishna Swaroop Kolluri has over 30 years of experience as a successful serial entrepreneur, CEO, senior operating executive, and venture capitalist Mr. Kolluri is a founding partner of Neotribe Ventures, an investment firm founded in 2017 that invests in breakthrough technology companies. Prior founding Neotribe, Mr. Kolluri was the General Partner of New Enterprise Associates from 2006 to 2016, focing on venture financing with early stage companies. Mr. Kolluri received a B.Tech. in Mechanical Engineering from the Indian Institute of Technology Madras, India, and his Masters in Indtrial Engineering from the University at Buffalo. - Krishna Swaroop Kolluri自2019年起担任董事会成员。Kolluri先生作为一名成功的连续创业者、首席执行官、高级运营主管和风险投资家，拥有超过30年的经验。Kolluri先生是Neotribe Ventures的创始合伙人，Neotribe Ventures是一家成立于2017年的投资公司，投资于突破性技术公司。在创立Neotribe之前，Kolluri先生曾于2006年至2016年担任New Enterprise Associates的普通合伙人，专注于早期公司的风险融资。Kolluri先生在印度马德拉斯印度理工学院获得机械工程学士学位，在布法罗大学获得工业工程硕士学位。
- Krishna Swaroop Kolluri has over 30 years of experience as a successful serial entrepreneur, CEO, senior operating executive, and venture capitalist Mr. Kolluri is a founding partner of Neotribe Ventures, an investment firm founded in 2017 that invests in breakthrough technology companies. Prior founding Neotribe, Mr. Kolluri was the General Partner of New Enterprise Associates from 2006 to 2016, focing on venture financing with early stage companies. Mr. Kolluri received a B.Tech. in Mechanical Engineering from the Indian Institute of Technology Madras, India, and his Masters in Indtrial Engineering from the University at Buffalo.
- Firat Ileri
-
Firat Ileri自2019年起担任董事会成员。Ileri先生目前是Hummingbird Ventures的管理合伙人，该公司是一家全球风险投资公司，管理着超过10亿美元的资产，他于2012年加入该公司。Ileri先生获得了电气工程和计算机科学以及管理科学的学士学位，以及电气工程和计算机科学的工程硕士学位，所有这些都来自马萨诸塞州理工学院。
Firat Ileri is currently the managing partner of Hummingbird Ventures a global venture capital firm with over $1 billion in assets under management, which he joined in 2012. Mr. Ileri earned his B.S. in electrical engineering and computer science and in management science, and a Masters of Engineering in electrical engineering and computer science, all from Massachetts Institute of Technology. - Firat Ileri自2019年起担任董事会成员。Ileri先生目前是Hummingbird Ventures的管理合伙人，该公司是一家全球风险投资公司，管理着超过10亿美元的资产，他于2012年加入该公司。Ileri先生获得了电气工程和计算机科学以及管理科学的学士学位，以及电气工程和计算机科学的工程硕士学位，所有这些都来自马萨诸塞州理工学院。
- Firat Ileri is currently the managing partner of Hummingbird Ventures a global venture capital firm with over $1 billion in assets under management, which he joined in 2012. Mr. Ileri earned his B.S. in electrical engineering and computer science and in management science, and a Masters of Engineering in electrical engineering and computer science, all from Massachetts Institute of Technology.
- David Tsao
-
David Tsao是总裁、首席技术官和联合创始人，自2016年成立以来一直在公司工作，同时还担任董事会成员。曹博士负责监督BillionToOne的所有技术发展。他获得了莱斯大学的生物工程博士学位，在那里他获得了纳米生物学培训奖学金。他以优异的成绩毕业于普林斯顿大学，获得物理学学士学位，辅修生物物理学和工程管理系统。在普林斯顿大学期间，他曾两次获得申斯通物理学奖。
David Tsao is President, Chief Technology Officer and Co Founder, having been with the Company since its inception in 2016, and also serves as a member of Board of Directors. Dr. Tsao oversees all technology developments at BillionToOne. He received a PhD in bioengineering from Rice University, where he was awarded a nanobiology training fellowship. He graduated cum laude from Princeton University with a bachelor's in physics and minors in biophysics and engineering management systems. While at Princeton, he was twice awarded the Shenstone Prize in physics. - David Tsao是总裁、首席技术官和联合创始人，自2016年成立以来一直在公司工作，同时还担任董事会成员。曹博士负责监督BillionToOne的所有技术发展。他获得了莱斯大学的生物工程博士学位，在那里他获得了纳米生物学培训奖学金。他以优异的成绩毕业于普林斯顿大学，获得物理学学士学位，辅修生物物理学和工程管理系统。在普林斯顿大学期间，他曾两次获得申斯通物理学奖。
- David Tsao is President, Chief Technology Officer and Co Founder, having been with the Company since its inception in 2016, and also serves as a member of Board of Directors. Dr. Tsao oversees all technology developments at BillionToOne. He received a PhD in bioengineering from Rice University, where he was awarded a nanobiology training fellowship. He graduated cum laude from Princeton University with a bachelor's in physics and minors in biophysics and engineering management systems. While at Princeton, he was twice awarded the Shenstone Prize in physics.
- Akshay Rai
-
Akshay Rai自2024年5月起担任董事会成员。Rai先生是一位专业投资者，在公共和私募股权投资方面拥有超过18年的经验，拥有医疗保健和生命科学方面的专注力。他目前领导Premji Invest的美国医疗保健投资，投资于成长阶段的私营公司。Rai先生自2010年7月以来一直在Premji Invest工作，并帮助该公司建立了美国医疗保健投资事务所，其中包括对Moderna、Devoted Health和Iora Health等公司的投资。在加入Premji Invest之前，Rai先生是印度花旗集团股票研究团队的一员。Rai先生拥有卡纳塔克邦国立理工学院的工程学士学位和印度班加罗尔管理学院的MBA学位。
Akshay Rai is a professional investor with over 18 years of experience investing in public and private equities, with a foc on healthcare and life sciences. He currently leads U.S. healthcare investments for Premji Invest, investing in growth stage private companies. Mr. Rai has been with Premji Invest since July 2010 and helped establish the U.S. healthcare investments practice for the firm, which includes investments in companies like Moderna, Devoted Health and Iora Health, among others. Prior to joining Premji Invest, Mr. Rai was part of the equity research team at Citigroup in India. Mr. Rai holds a bachelor of engineering degree from National Institute of Technology Karnataka and an MBA from the Indian Institute of Management Bangalore. - Akshay Rai自2024年5月起担任董事会成员。Rai先生是一位专业投资者，在公共和私募股权投资方面拥有超过18年的经验，拥有医疗保健和生命科学方面的专注力。他目前领导Premji Invest的美国医疗保健投资，投资于成长阶段的私营公司。Rai先生自2010年7月以来一直在Premji Invest工作，并帮助该公司建立了美国医疗保健投资事务所，其中包括对Moderna、Devoted Health和Iora Health等公司的投资。在加入Premji Invest之前，Rai先生是印度花旗集团股票研究团队的一员。Rai先生拥有卡纳塔克邦国立理工学院的工程学士学位和印度班加罗尔管理学院的MBA学位。
- Akshay Rai is a professional investor with over 18 years of experience investing in public and private equities, with a foc on healthcare and life sciences. He currently leads U.S. healthcare investments for Premji Invest, investing in growth stage private companies. Mr. Rai has been with Premji Invest since July 2010 and helped establish the U.S. healthcare investments practice for the firm, which includes investments in companies like Moderna, Devoted Health and Iora Health, among others. Prior to joining Premji Invest, Mr. Rai was part of the equity research team at Citigroup in India. Mr. Rai holds a bachelor of engineering degree from National Institute of Technology Karnataka and an MBA from the Indian Institute of Management Bangalore.
高管简历
中英对照 | 中文 | 英文- Ross Taylor
Ross Taylor，他曾一直担任BillionToOne，Inc.首席财务官、财务副总裁和秘书（2015年8月以来）。他于2014年10月加入公司，并担任副总裁，负责业务发展和投资者关系。从2005年到2014年，他曾担任CL King & Associates公司（投资银行公司）的高级副总裁、股票研究分析师。
Ross Taylor has served as Chief Financial Officer since January 2024. Prior to joining BillionToOne, Mr. Taylor was Chief Financial Officer for Codexis, Inc., a publicly traded enzyme engineering company, from 2019 to February 2023. Previoly, he served as Chief Financial Officer of Abaxis, Inc., a publicly traded medical technology company, acquired by Zoetis for $2.0 billion. At Abaxis, he first held the role of Vice President of Biness Development & Investor Relations from 2014 to 2015, before being appointed CFO from Augt 2015 through the company's successful acquisition in July 2018. Early in his career, Mr. Taylor spent more than a decade as an equity research analyst at leading Wall Street firms including CL King & Associates, UBS, Smith Barney, and CJ Lawrence, providing deep expertise in capital markets and strategic financial planning. Mr. Taylor holds an MBA from Columbia Biness School and a B.A. in economics from Duke University.- Ross Taylor，他曾一直担任BillionToOne，Inc.首席财务官、财务副总裁和秘书（2015年8月以来）。他于2014年10月加入公司，并担任副总裁，负责业务发展和投资者关系。从2005年到2014年，他曾担任CL King & Associates公司（投资银行公司）的高级副总裁、股票研究分析师。
- Ross Taylor has served as Chief Financial Officer since January 2024. Prior to joining BillionToOne, Mr. Taylor was Chief Financial Officer for Codexis, Inc., a publicly traded enzyme engineering company, from 2019 to February 2023. Previoly, he served as Chief Financial Officer of Abaxis, Inc., a publicly traded medical technology company, acquired by Zoetis for $2.0 billion. At Abaxis, he first held the role of Vice President of Biness Development & Investor Relations from 2014 to 2015, before being appointed CFO from Augt 2015 through the company's successful acquisition in July 2018. Early in his career, Mr. Taylor spent more than a decade as an equity research analyst at leading Wall Street firms including CL King & Associates, UBS, Smith Barney, and CJ Lawrence, providing deep expertise in capital markets and strategic financial planning. Mr. Taylor holds an MBA from Columbia Biness School and a B.A. in economics from Duke University.
- Thomas Lynch
Thomas Lynch于2022年10月加入BillionToOne担任总法律顾问。Lynch先生拥有20多年领导法律团队的经验。在加入之前，从2021年4月到2022年10月，他担任Fortive Corporation（连接工作流解决方案技术的公开交易提供商）高级医疗保健解决方案的首席合规官。从2018年到2021年4月，Lynch先生担任上市医疗器械公司Nullis的首席法律官。从2015年到2018年，Lynch先生担任Orexigen Therapeutics（一家上市的生物技术公司）的首席行政官兼总法律顾问，该公司于2018年3月提交了第11章破产自愿申请。2018年6月，Lynch先生被任命为Orexigen Therapeutics的总裁，负责管理其重组。在职业生涯早期，Lynch先生还在Boston Scientific Corporation和Novartis Pharma担任各种高级法律和合规职位。他的法律生涯始于Dorsey & Whitney LLP.他持有斯坦福大学的历史学士学位、Boston College Law School的法学博士学位和St. Thomas大学的教学硕士学位，在那里他担任法学兼职教授。
Thomas Lynch joined BillionToOne as General Counsel in October 2022. Mr. Lynch hass over two decades of experience leading legal teams. Prior to joining , he served as Chief Compliance Officer, Advanced Healthcare Solutions at Fortive Corporation, a publicly traded provider of connected workflow solutions technologies, from April 2021 to October 2022. From 2018 to April 2021, Mr. Lynch served as the Chief Legal Officer at Nullis, a publicly traded medical device company. From 2015 to 2018, Mr. Lynch served as the Chief Administrative Officer and General Counsel at Orexigen Therapeutics, a publicly traded biotechnology company, which filed a voluntary petition for Chapter 11 bankruptcy in March 2018. In June 2018, Mr. Lynch was appointed as president of Orexigen Therapeutics to manage its restructuring. Mr. Lynch also held vario senior legal and compliance positions at Boston Scientific Corporation and Novartis Pharma, earlier in his career. Mr. Lynch began his legal career at Dorsey & Whitney LLP. Mr. Lynch earned a B.A. in history from Stanford University, a JD from Boston College Law School and an MA in teaching from the University of St. Thomas, where he serves as an Adjunct Professor of Law.- Thomas Lynch于2022年10月加入BillionToOne担任总法律顾问。Lynch先生拥有20多年领导法律团队的经验。在加入之前，从2021年4月到2022年10月，他担任Fortive Corporation（连接工作流解决方案技术的公开交易提供商）高级医疗保健解决方案的首席合规官。从2018年到2021年4月，Lynch先生担任上市医疗器械公司Nullis的首席法律官。从2015年到2018年，Lynch先生担任Orexigen Therapeutics（一家上市的生物技术公司）的首席行政官兼总法律顾问，该公司于2018年3月提交了第11章破产自愿申请。2018年6月，Lynch先生被任命为Orexigen Therapeutics的总裁，负责管理其重组。在职业生涯早期，Lynch先生还在Boston Scientific Corporation和Novartis Pharma担任各种高级法律和合规职位。他的法律生涯始于Dorsey & Whitney LLP.他持有斯坦福大学的历史学士学位、Boston College Law School的法学博士学位和St. Thomas大学的教学硕士学位，在那里他担任法学兼职教授。
- Thomas Lynch joined BillionToOne as General Counsel in October 2022. Mr. Lynch hass over two decades of experience leading legal teams. Prior to joining , he served as Chief Compliance Officer, Advanced Healthcare Solutions at Fortive Corporation, a publicly traded provider of connected workflow solutions technologies, from April 2021 to October 2022. From 2018 to April 2021, Mr. Lynch served as the Chief Legal Officer at Nullis, a publicly traded medical device company. From 2015 to 2018, Mr. Lynch served as the Chief Administrative Officer and General Counsel at Orexigen Therapeutics, a publicly traded biotechnology company, which filed a voluntary petition for Chapter 11 bankruptcy in March 2018. In June 2018, Mr. Lynch was appointed as president of Orexigen Therapeutics to manage its restructuring. Mr. Lynch also held vario senior legal and compliance positions at Boston Scientific Corporation and Novartis Pharma, earlier in his career. Mr. Lynch began his legal career at Dorsey & Whitney LLP. Mr. Lynch earned a B.A. in history from Stanford University, a JD from Boston College Law School and an MA in teaching from the University of St. Thomas, where he serves as an Adjunct Professor of Law.
- Shan Riku Sakakibara
Shan Riku Sakakibara于2019年作为首批员工之一加入BillionToOne，目前担任首席产品官。在担任首席产品官之前，Riku Sakakibara女士曾担任其他行政职务，最近担任产品高级副总裁。Riku Sakakibara女士在BillionToOne负责监督临床和软件产品管理、市场营销、转化研究以及临床和医疗事务。Riku Sakakibara女士在推出和管理从软件产品到精准诊断临床分析的广泛产品方面拥有超过15年的经验。Previoly，Riku Sakakibara女士于2015年至2017年在Natera，Inc.担任高级产品经理和投资组合策略经理。Riku Sakakibara女士的职业生涯始于麦肯锡公司，她曾在《财富》100强公司工作。Riku Sakakibara女士毕业于麻省理工学院化学学士学位，拥有斯坦福大学MBA学位和哈佛大学MPA/ID。
Shan Riku Sakakibara joined BillionToOne in 2019 as one of first employees and currently serves as Chief Product Officer. Prior to her role as Chief Product Officer, Ms. Riku Sakakibara served in other executive positions, most recently as Senior Vice President of Product. Ms. Riku Sakakibara oversees both clinical and software product management, marketing, translational research, and clinical and medical affairs at BillionToOne. Ms. Riku Sakakibara has over 15 years of experience in launching and managing a wide range of products from software products to precision diagnostics clinical assays. Previoly, Ms. Riku Sakakibara served as a Senior Product Manager and Portfolio Strategy Manager at Natera, Inc. from 2015 to 2017. Ms. Riku Sakakibara started her career at McKinsey & Co., where she worked with Fortune 100 companies. Ms. Riku Sakakibara graduated with a B.S. in chemistry from Massachetts Institute of Technology, holds an MBA from Stanford University, and an MPA/ID from Harvard University.- Shan Riku Sakakibara于2019年作为首批员工之一加入BillionToOne，目前担任首席产品官。在担任首席产品官之前，Riku Sakakibara女士曾担任其他行政职务，最近担任产品高级副总裁。Riku Sakakibara女士在BillionToOne负责监督临床和软件产品管理、市场营销、转化研究以及临床和医疗事务。Riku Sakakibara女士在推出和管理从软件产品到精准诊断临床分析的广泛产品方面拥有超过15年的经验。Previoly，Riku Sakakibara女士于2015年至2017年在Natera，Inc.担任高级产品经理和投资组合策略经理。Riku Sakakibara女士的职业生涯始于麦肯锡公司，她曾在《财富》100强公司工作。Riku Sakakibara女士毕业于麻省理工学院化学学士学位，拥有斯坦福大学MBA学位和哈佛大学MPA/ID。
- Shan Riku Sakakibara joined BillionToOne in 2019 as one of first employees and currently serves as Chief Product Officer. Prior to her role as Chief Product Officer, Ms. Riku Sakakibara served in other executive positions, most recently as Senior Vice President of Product. Ms. Riku Sakakibara oversees both clinical and software product management, marketing, translational research, and clinical and medical affairs at BillionToOne. Ms. Riku Sakakibara has over 15 years of experience in launching and managing a wide range of products from software products to precision diagnostics clinical assays. Previoly, Ms. Riku Sakakibara served as a Senior Product Manager and Portfolio Strategy Manager at Natera, Inc. from 2015 to 2017. Ms. Riku Sakakibara started her career at McKinsey & Co., where she worked with Fortune 100 companies. Ms. Riku Sakakibara graduated with a B.S. in chemistry from Massachetts Institute of Technology, holds an MBA from Stanford University, and an MPA/ID from Harvard University.
- John ten Bosch
John Ten Bosch于2020年9月加入BillionToOne，担任实验室主任，此后多次晋升，最近担任实验室运营高级副总裁。Ten Bosch博士带来了超过15年领导高复杂性CLIA实验室的经验，在监管、临床实验室运营和测试开发方面拥有专业知识。在加入BillionToOne之前，他于2012年至2020年在Kaiser Permanente工作，担任分子病理学和细胞遗传学实验室的实验室主任和质量主任。Ten Bosch博士以优异成绩毕业于加州大学戴维斯分校，获得遗传学学士学位。他在加州大学伯克利分校获得分子和细胞生物学博士学位，并在斯坦福大学和加州大学洛杉矶分校完成博士后研究。
John ten Bosch joined BillionToOne in September 2020 as Laboratory Director and has since been promoted multiple times, most recently to the role of Senior Vice President of Laboratory Operations. Dr. ten Bosch hass over 15 years of experience leading high complexity CLIA laboratories, with expertise in regulatory oversight, clinical laboratory operations, and test development. Prior to joining BillionToOne, he worked at Kaiser Permanente from 2012 to 2020, where he served as both Laboratory Director and Director of Quality for the Molecular Pathology and Cytogenetics laboratories. Dr. ten Bosch graduated magna cum laude from the University of California, Davis with a B.S. in Genetics. He earned his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and completed postdoctoral fellowships at Stanford and UCLA.- John Ten Bosch于2020年9月加入BillionToOne，担任实验室主任，此后多次晋升，最近担任实验室运营高级副总裁。Ten Bosch博士带来了超过15年领导高复杂性CLIA实验室的经验，在监管、临床实验室运营和测试开发方面拥有专业知识。在加入BillionToOne之前，他于2012年至2020年在Kaiser Permanente工作，担任分子病理学和细胞遗传学实验室的实验室主任和质量主任。Ten Bosch博士以优异成绩毕业于加州大学戴维斯分校，获得遗传学学士学位。他在加州大学伯克利分校获得分子和细胞生物学博士学位，并在斯坦福大学和加州大学洛杉矶分校完成博士后研究。
- John ten Bosch joined BillionToOne in September 2020 as Laboratory Director and has since been promoted multiple times, most recently to the role of Senior Vice President of Laboratory Operations. Dr. ten Bosch hass over 15 years of experience leading high complexity CLIA laboratories, with expertise in regulatory oversight, clinical laboratory operations, and test development. Prior to joining BillionToOne, he worked at Kaiser Permanente from 2012 to 2020, where he served as both Laboratory Director and Director of Quality for the Molecular Pathology and Cytogenetics laboratories. Dr. ten Bosch graduated magna cum laude from the University of California, Davis with a B.S. in Genetics. He earned his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and completed postdoctoral fellowships at Stanford and UCLA.
- Oguzhan Atay
Oguzhan Atay是首席执行官兼联合创始人，自2016年成立以来一直领导该公司，同时还担任董事会主席。Atay博士在斯坦福大学获得生物学博士学位，他的工作发表在Cell Systems的封面上。他以优异成绩和Phi Beta Kappa成绩毕业于普林斯顿大学，获得分子生物学学士学位，并辅修物理学、计算机科学和应用数学。
Oguzhan Atay is Chief Executive Officer and Co Founder, having led the Company since its inception in 2016, and also serves as the Chair of Board of Directors. Dr. Atay received his PhD in Biology from Stanford University, where his work was published on the cover of Cell Systems. He graduated summa cum laude and Phi Beta Kappa from Princeton University with a bachelor's in molecular biology and minors in physics, computer science, and applied mathematics.- Oguzhan Atay是首席执行官兼联合创始人，自2016年成立以来一直领导该公司，同时还担任董事会主席。Atay博士在斯坦福大学获得生物学博士学位，他的工作发表在Cell Systems的封面上。他以优异成绩和Phi Beta Kappa成绩毕业于普林斯顿大学，获得分子生物学学士学位，并辅修物理学、计算机科学和应用数学。
- Oguzhan Atay is Chief Executive Officer and Co Founder, having led the Company since its inception in 2016, and also serves as the Chair of Board of Directors. Dr. Atay received his PhD in Biology from Stanford University, where his work was published on the cover of Cell Systems. He graduated summa cum laude and Phi Beta Kappa from Princeton University with a bachelor's in molecular biology and minors in physics, computer science, and applied mathematics.
- John Lister
John Lister于2025年7月加入BillionToOne，担任首席行政官。在加入BillionToOne之前，李斯特先生在2022年6月至2025年6月期间担任糖尿病软件公司Tidepool项目的首席运营官。从2020年1月到2023年1月，Lister先生为医疗保健领域的公司提供战略商业、公司融资和法律建议，包括Tandem Diabetes、Zoe Global、WaveForm Diabetes和Candid Dental。Previoly，Lister先生于2008年至2019年任职于连续血糖监测系统的上市生产商德康医疗公司。Lister先生曾在德康医疗担任多个高管职务，包括2008年至2015年担任总法律顾问兼人力资源主管，以及2015年至2019年担任德康医疗国际BINES的总经理。李斯特先生的职业生涯始于Fenwick & ST LLP的律师。李斯特先生拥有克莱蒙特麦肯纳学院的政府和文学学士学位以及旧金山大学法学院的京东学位。
John Lister joined BillionToOne in July 2025 as Chief Administrative Officer. Prior to joining BillionToOne, Mr. Lister served as Chief Operating Officer of the Tidepool Project, a diabetes software company, from June 2022 through June 2025. From January 2020 through January 2023, Mr. Lister provided strategic commercial, corporate finance and legal advice to companies in the healthcare space, including Tandem Diabetes, Zoe Global, WaveForm Diabetes and Candid Dental. Previoly, Mr. Lister worked for Dexcom, Inc., a publicly traded producer of continuo glucose monitoring systems, from 2008 to 2019. Mr Lister served in vario executive positions at Dexcom, including as General Counsel & Head of Human Resces from 2008 to 2015, and as General Manager for Dexcom's International biness from 2015 to 2019. Mr. Lister began his career as an attorney at Fenwick & st LLP. Mr. Lister earned a B.A. in government and literature from Claremont McKenna College and a JD from University of San Francisco Law School.- John Lister于2025年7月加入BillionToOne，担任首席行政官。在加入BillionToOne之前，李斯特先生在2022年6月至2025年6月期间担任糖尿病软件公司Tidepool项目的首席运营官。从2020年1月到2023年1月，Lister先生为医疗保健领域的公司提供战略商业、公司融资和法律建议，包括Tandem Diabetes、Zoe Global、WaveForm Diabetes和Candid Dental。Previoly，Lister先生于2008年至2019年任职于连续血糖监测系统的上市生产商德康医疗公司。Lister先生曾在德康医疗担任多个高管职务，包括2008年至2015年担任总法律顾问兼人力资源主管，以及2015年至2019年担任德康医疗国际BINES的总经理。李斯特先生的职业生涯始于Fenwick & ST LLP的律师。李斯特先生拥有克莱蒙特麦肯纳学院的政府和文学学士学位以及旧金山大学法学院的京东学位。
- John Lister joined BillionToOne in July 2025 as Chief Administrative Officer. Prior to joining BillionToOne, Mr. Lister served as Chief Operating Officer of the Tidepool Project, a diabetes software company, from June 2022 through June 2025. From January 2020 through January 2023, Mr. Lister provided strategic commercial, corporate finance and legal advice to companies in the healthcare space, including Tandem Diabetes, Zoe Global, WaveForm Diabetes and Candid Dental. Previoly, Mr. Lister worked for Dexcom, Inc., a publicly traded producer of continuo glucose monitoring systems, from 2008 to 2019. Mr Lister served in vario executive positions at Dexcom, including as General Counsel & Head of Human Resces from 2008 to 2015, and as General Manager for Dexcom's International biness from 2015 to 2019. Mr. Lister began his career as an attorney at Fenwick & st LLP. Mr. Lister earned a B.A. in government and literature from Claremont McKenna College and a JD from University of San Francisco Law School.
- David Tsao
David Tsao是总裁、首席技术官和联合创始人，自2016年成立以来一直在公司工作，同时还担任董事会成员。曹博士负责监督BillionToOne的所有技术发展。他获得了莱斯大学的生物工程博士学位，在那里他获得了纳米生物学培训奖学金。他以优异的成绩毕业于普林斯顿大学，获得物理学学士学位，辅修生物物理学和工程管理系统。在普林斯顿大学期间，他曾两次获得申斯通物理学奖。
David Tsao is President, Chief Technology Officer and Co Founder, having been with the Company since its inception in 2016, and also serves as a member of Board of Directors. Dr. Tsao oversees all technology developments at BillionToOne. He received a PhD in bioengineering from Rice University, where he was awarded a nanobiology training fellowship. He graduated cum laude from Princeton University with a bachelor's in physics and minors in biophysics and engineering management systems. While at Princeton, he was twice awarded the Shenstone Prize in physics.- David Tsao是总裁、首席技术官和联合创始人，自2016年成立以来一直在公司工作，同时还担任董事会成员。曹博士负责监督BillionToOne的所有技术发展。他获得了莱斯大学的生物工程博士学位，在那里他获得了纳米生物学培训奖学金。他以优异的成绩毕业于普林斯顿大学，获得物理学学士学位，辅修生物物理学和工程管理系统。在普林斯顿大学期间，他曾两次获得申斯通物理学奖。
- David Tsao is President, Chief Technology Officer and Co Founder, having been with the Company since its inception in 2016, and also serves as a member of Board of Directors. Dr. Tsao oversees all technology developments at BillionToOne. He received a PhD in bioengineering from Rice University, where he was awarded a nanobiology training fellowship. He graduated cum laude from Princeton University with a bachelor's in physics and minors in biophysics and engineering management systems. While at Princeton, he was twice awarded the Shenstone Prize in physics.
- Nancy Johnson
南希·约翰逊于2019年4月加入BillionToOne，甚至在产品最初商业化之前，就已经建立了产前和肿瘤商业组织，担任销售和商业运营高级副总裁。Johnson女士带来了在初创和大型销售组织中20多年的诊断销售领导经验。最近，约翰逊女士在分子信息上市公司Foundation Medicine的商业战略和执行方面发挥了关键作用，该公司在她任职期间被罗氏收购。在加入Foundation Medicine之前，她曾在vario分子诊断公司担任多个商业领导职务。约翰逊女士的职业生涯始于董事会认证的医疗技术专家，并获得了克赖顿大学的医疗技术学士学位。
Nancy Johnson joined BillionToOne in April 2019, even prior to the initial commercialization of products, and has built both prenatal and oncology commercial organizations as Senior Vice President of Sales and Commercial Operations. Ms. Johnson hass more than 20 years of diagnostic sales leadership experience in both start up and large scale sales organizations. Most recently, Ms. Johnson played a key role in commercial strategy and execution at Foundation Medicine, a publicly traded molecular information company, that was acquired by Roche during her tenure. Prior to Foundation Medicine, she held several commercial leadership positions at vario molecular diagnostic companies. Ms. Johnson started her career as a board certified Medical Technologist and earned a B.S. in medical technology from Creighton University.- 南希·约翰逊于2019年4月加入BillionToOne，甚至在产品最初商业化之前，就已经建立了产前和肿瘤商业组织，担任销售和商业运营高级副总裁。Johnson女士带来了在初创和大型销售组织中20多年的诊断销售领导经验。最近，约翰逊女士在分子信息上市公司Foundation Medicine的商业战略和执行方面发挥了关键作用，该公司在她任职期间被罗氏收购。在加入Foundation Medicine之前，她曾在vario分子诊断公司担任多个商业领导职务。约翰逊女士的职业生涯始于董事会认证的医疗技术专家，并获得了克赖顿大学的医疗技术学士学位。
- Nancy Johnson joined BillionToOne in April 2019, even prior to the initial commercialization of products, and has built both prenatal and oncology commercial organizations as Senior Vice President of Sales and Commercial Operations. Ms. Johnson hass more than 20 years of diagnostic sales leadership experience in both start up and large scale sales organizations. Most recently, Ms. Johnson played a key role in commercial strategy and execution at Foundation Medicine, a publicly traded molecular information company, that was acquired by Roche during her tenure. Prior to Foundation Medicine, she held several commercial leadership positions at vario molecular diagnostic companies. Ms. Johnson started her career as a board certified Medical Technologist and earned a B.S. in medical technology from Creighton University.